TY - JOUR
T1 - Impact of body mass index on overall survival in patients with metastatic breast cancer
AU - Saleh, Khalil
AU - Carton, Matthieu
AU - Dieras, Véronique
AU - Heudel, Pierre Etienne
AU - Brain, Etienne
AU - D'Hondt, Véronique
AU - Mailliez, Audrey
AU - Patsouris, Anne
AU - Mouret-Reynier, Marie Ange
AU - Goncalves, Anthony
AU - Ferrero, Jean Marc
AU - Petit, Thierry
AU - Emile, George
AU - Uwer, Lionel
AU - Debled, Marc
AU - Dalenc, Florence
AU - Jouannaud, Christelle
AU - Ladoire, Sylvain
AU - Leheurteur, Marianne
AU - Cottu, Paul
AU - Veron, Lucie
AU - Savignoni, Alexia
AU - Courtinard, Coralie
AU - Robain, Mathieu
AU - Delaloge, Suzette
AU - Deluche, Elise
N1 - Publisher Copyright:
© 2020 The Author(s)
PY - 2021/2/1
Y1 - 2021/2/1
N2 - Background: High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC). Methods: The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers. Results: Of 22 463 patients in ESME-MBC, 12 999 women had BMI data available at MBC diagnosis. Median BMI was 24.9 kg/m2 (range 12.1–66.5); 20% of women were obese and 5% underweight. Obesity was associated with more de novo MBC, while underweight patients had more aggressive cancer features. Median overall survival (OS) of the BMI cohort was 47.4 months (95% CI [46.2–48.5]) (median follow-up: 48.6 months). Underweight was independently associated with a worse OS (median OS 33 months; HR 1.14, 95%CI, 1.02–1.27) and first line progression-free survival (HR, 1.11; 95%CI, 1.01; 1.22), while overweight or obesity had no effect. Conclusion: Overweight and obesity are not associated with poorer outcomes in women with metastatic disease, while underweight appears as an independent adverse prognostic factor.
AB - Background: High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC). Methods: The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers. Results: Of 22 463 patients in ESME-MBC, 12 999 women had BMI data available at MBC diagnosis. Median BMI was 24.9 kg/m2 (range 12.1–66.5); 20% of women were obese and 5% underweight. Obesity was associated with more de novo MBC, while underweight patients had more aggressive cancer features. Median overall survival (OS) of the BMI cohort was 47.4 months (95% CI [46.2–48.5]) (median follow-up: 48.6 months). Underweight was independently associated with a worse OS (median OS 33 months; HR 1.14, 95%CI, 1.02–1.27) and first line progression-free survival (HR, 1.11; 95%CI, 1.01; 1.22), while overweight or obesity had no effect. Conclusion: Overweight and obesity are not associated with poorer outcomes in women with metastatic disease, while underweight appears as an independent adverse prognostic factor.
KW - BMI
KW - Metastatic breast cancer
KW - Obesity
KW - Overall survival
KW - Underweight
UR - http://www.scopus.com/inward/record.url?scp=85097477568&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2020.11.014
DO - 10.1016/j.breast.2020.11.014
M3 - Article
C2 - 33307392
AN - SCOPUS:85097477568
SN - 0960-9776
VL - 55
SP - 16
EP - 24
JO - Breast
JF - Breast
ER -